Optimized Treatment and Regression of HBV-induced Liver Fibrosis

Inclusion criteria

• Ages from 18 to 65 years old;
• Male or female;
• Treatment-naive patients with chronic HBV-induced fibrosis S2/S3 (similar to F2/F3, Ishak 2/3/4), who consent to undergo liver biopsy before and after treatment;
• Patients with HBeAg-positive, HBVDNA>2×10<4> IU/ml or with HBeAg-negative, HBVDNA>2×10<3> IU/ml;
• Agree to be follow-up regularly;
• signature of written inform consent.

Exclusion criteria

• Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy, esophageal varices bleeding or other complications of decompensated cirrhosis or hepatocelluar carcinoma;
• Patients who are allergic to entecavir, interferon, or their components, and those considered not suitable for medications used in this study;
• Patients coinfection with HCV or HIV, alcoholic liver disease, autoimmune liver disease, genetic liver disease, drug-induced liver injury, severe non-alcoholic fatty liver disease or other chronic liver diseases;
• Patients with baseline AFP level higher than 100 ng/ml and possible malignant lesion on image, or AFP level higher than 100 ng/ml for continuous three months;
• Creatinine >1.5×ULN;
• Patients with other uncured malignant tumors;
• Patients with severe diseases of heart, lung, kidney, brain, blood system or other organs;
• Patients with severe neurological or psychological disease (e.g. epilepsy, depression, mania and schizophrenia);
• Patients with poorly controlled diabetes, hypertension or thyroid disease;
• Patients with any other reasons not suitable for the study.